Creative Medical Technology Holdings, Inc. (CELZ)
(Delayed Data from NSDQ)
$3.57 USD
-0.24 (-6.28%)
Updated Jul 8, 2024 03:50 PM ET
After-Market: $3.66 +0.09 (2.52%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CELZ 3.57 -0.24(-6.28%)
Will CELZ be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CELZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CELZ
Creative Medical (CELZ) Up on Orphan Drug Tag for CELZ-101
Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?
CELZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Creative Medical Technology Holdings, Inc. (CELZ) a New Buy Stock
Creative Medical (CELZ) Up 86% on Upbeat Diabetes Study Data
Other News for CELZ
Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelzĀ® ProgramĀ with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin
Creative Medical Technology announces development of IPSCelz program
CELZ Stock Earnings: Creative Medical Tech Beats EPS for Q1 2024